Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

C. Pellegrini, A. Broccoli, A. Pulsoni, L. Rigacci, C. Patti, G. Gini, D. Mannina, M. Tani, C. Rusconi, A. Romano, A. Vanazzi, B. Botto, A. Santoro, S. Hoaus, G.M. Rigolin, P. Musto, P. Mazza, S. Molica, P. Corradini, A. FamaF. Gaudio, M. Merli, F. Ronconi, G. Gritti, D. Vallisa, P. Tosi, A.M. Liberati, A. Pinto, V. Pavone, F. Gherlinzoni, M.P. Bianchi, S. Volpetti, L. Trentin, M.C. Goldaniga, M. Bonfichi, A.D. Renzo, C. Schiavotto, M. Spina, A.M. Carella, V. Stefoni, L. Argnani, P.L. Zinzani

Research output: Contribution to journalArticle

8 Citations (Scopus)
Original languageEnglish
Pages (from-to)91703-91710
Number of pages8
JournalOncotarget
Volume8
Issue number53
DOIs
Publication statusPublished - 2017

Keywords

  • brentuximab vedotin
  • CD30 antigen, acute myeloid leukemia
  • adult
  • adult respiratory distress syndrome
  • aged
  • allogeneic stem cell transplantation
  • Article
  • cancer recurrence
  • clinical practice
  • disease free survival
  • disease severity
  • drug dose reduction
  • drug efficacy
  • drug response
  • drug safety
  • drug tolerability
  • female
  • follow up
  • histopathology
  • Hodgkin disease
  • human
  • incidence
  • Italy
  • major clinical study
  • male
  • multiple cycle treatment
  • neutropenia
  • observational study
  • overall survival
  • pancreatitis
  • pancytopenia
  • peripheral neuropathy
  • personal experience
  • progression free survival
  • respiratory failure
  • retrospective study
  • sensory neuropathy
  • thrombocytopenia
  • treatment duration

Cite this

Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. / Pellegrini, C.; Broccoli, A.; Pulsoni, A.; Rigacci, L.; Patti, C.; Gini, G.; Mannina, D.; Tani, M.; Rusconi, C.; Romano, A.; Vanazzi, A.; Botto, B.; Santoro, A.; Hoaus, S.; Rigolin, G.M.; Musto, P.; Mazza, P.; Molica, S.; Corradini, P.; Fama, A.; Gaudio, F.; Merli, M.; Ronconi, F.; Gritti, G.; Vallisa, D.; Tosi, P.; Liberati, A.M.; Pinto, A.; Pavone, V.; Gherlinzoni, F.; Bianchi, M.P.; Volpetti, S.; Trentin, L.; Goldaniga, M.C.; Bonfichi, M.; Renzo, A.D.; Schiavotto, C.; Spina, M.; Carella, A.M.; Stefoni, V.; Argnani, L.; Zinzani, P.L.

In: Oncotarget, Vol. 8, No. 53, 2017, p. 91703-91710.

Research output: Contribution to journalArticle

Pellegrini, C, Broccoli, A, Pulsoni, A, Rigacci, L, Patti, C, Gini, G, Mannina, D, Tani, M, Rusconi, C, Romano, A, Vanazzi, A, Botto, B, Santoro, A, Hoaus, S, Rigolin, GM, Musto, P, Mazza, P, Molica, S, Corradini, P, Fama, A, Gaudio, F, Merli, M, Ronconi, F, Gritti, G, Vallisa, D, Tosi, P, Liberati, AM, Pinto, A, Pavone, V, Gherlinzoni, F, Bianchi, MP, Volpetti, S, Trentin, L, Goldaniga, MC, Bonfichi, M, Renzo, AD, Schiavotto, C, Spina, M, Carella, AM, Stefoni, V, Argnani, L & Zinzani, PL 2017, 'Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma', Oncotarget, vol. 8, no. 53, pp. 91703-91710. https://doi.org/10.18632/oncotarget.18114
Pellegrini, C. ; Broccoli, A. ; Pulsoni, A. ; Rigacci, L. ; Patti, C. ; Gini, G. ; Mannina, D. ; Tani, M. ; Rusconi, C. ; Romano, A. ; Vanazzi, A. ; Botto, B. ; Santoro, A. ; Hoaus, S. ; Rigolin, G.M. ; Musto, P. ; Mazza, P. ; Molica, S. ; Corradini, P. ; Fama, A. ; Gaudio, F. ; Merli, M. ; Ronconi, F. ; Gritti, G. ; Vallisa, D. ; Tosi, P. ; Liberati, A.M. ; Pinto, A. ; Pavone, V. ; Gherlinzoni, F. ; Bianchi, M.P. ; Volpetti, S. ; Trentin, L. ; Goldaniga, M.C. ; Bonfichi, M. ; Renzo, A.D. ; Schiavotto, C. ; Spina, M. ; Carella, A.M. ; Stefoni, V. ; Argnani, L. ; Zinzani, P.L. / Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. In: Oncotarget. 2017 ; Vol. 8, No. 53. pp. 91703-91710.
@article{a90c47f243b74066bc715ae290179505,
title = "Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma",
keywords = "brentuximab vedotin, CD30 antigen, acute myeloid leukemia, adult, adult respiratory distress syndrome, aged, allogeneic stem cell transplantation, Article, cancer recurrence, clinical practice, disease free survival, disease severity, drug dose reduction, drug efficacy, drug response, drug safety, drug tolerability, female, follow up, histopathology, Hodgkin disease, human, incidence, Italy, major clinical study, male, multiple cycle treatment, neutropenia, observational study, overall survival, pancreatitis, pancytopenia, peripheral neuropathy, personal experience, progression free survival, respiratory failure, retrospective study, sensory neuropathy, thrombocytopenia, treatment duration",
author = "C. Pellegrini and A. Broccoli and A. Pulsoni and L. Rigacci and C. Patti and G. Gini and D. Mannina and M. Tani and C. Rusconi and A. Romano and A. Vanazzi and B. Botto and A. Santoro and S. Hoaus and G.M. Rigolin and P. Musto and P. Mazza and S. Molica and P. Corradini and A. Fama and F. Gaudio and M. Merli and F. Ronconi and G. Gritti and D. Vallisa and P. Tosi and A.M. Liberati and A. Pinto and V. Pavone and F. Gherlinzoni and M.P. Bianchi and S. Volpetti and L. Trentin and M.C. Goldaniga and M. Bonfichi and A.D. Renzo and C. Schiavotto and M. Spina and A.M. Carella and V. Stefoni and L. Argnani and P.L. Zinzani",
note = "cited By 0",
year = "2017",
doi = "10.18632/oncotarget.18114",
language = "English",
volume = "8",
pages = "91703--91710",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "53",

}

TY - JOUR

T1 - Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

AU - Pellegrini, C.

AU - Broccoli, A.

AU - Pulsoni, A.

AU - Rigacci, L.

AU - Patti, C.

AU - Gini, G.

AU - Mannina, D.

AU - Tani, M.

AU - Rusconi, C.

AU - Romano, A.

AU - Vanazzi, A.

AU - Botto, B.

AU - Santoro, A.

AU - Hoaus, S.

AU - Rigolin, G.M.

AU - Musto, P.

AU - Mazza, P.

AU - Molica, S.

AU - Corradini, P.

AU - Fama, A.

AU - Gaudio, F.

AU - Merli, M.

AU - Ronconi, F.

AU - Gritti, G.

AU - Vallisa, D.

AU - Tosi, P.

AU - Liberati, A.M.

AU - Pinto, A.

AU - Pavone, V.

AU - Gherlinzoni, F.

AU - Bianchi, M.P.

AU - Volpetti, S.

AU - Trentin, L.

AU - Goldaniga, M.C.

AU - Bonfichi, M.

AU - Renzo, A.D.

AU - Schiavotto, C.

AU - Spina, M.

AU - Carella, A.M.

AU - Stefoni, V.

AU - Argnani, L.

AU - Zinzani, P.L.

N1 - cited By 0

PY - 2017

Y1 - 2017

KW - brentuximab vedotin

KW - CD30 antigen, acute myeloid leukemia

KW - adult

KW - adult respiratory distress syndrome

KW - aged

KW - allogeneic stem cell transplantation

KW - Article

KW - cancer recurrence

KW - clinical practice

KW - disease free survival

KW - disease severity

KW - drug dose reduction

KW - drug efficacy

KW - drug response

KW - drug safety

KW - drug tolerability

KW - female

KW - follow up

KW - histopathology

KW - Hodgkin disease

KW - human

KW - incidence

KW - Italy

KW - major clinical study

KW - male

KW - multiple cycle treatment

KW - neutropenia

KW - observational study

KW - overall survival

KW - pancreatitis

KW - pancytopenia

KW - peripheral neuropathy

KW - personal experience

KW - progression free survival

KW - respiratory failure

KW - retrospective study

KW - sensory neuropathy

KW - thrombocytopenia

KW - treatment duration

U2 - 10.18632/oncotarget.18114

DO - 10.18632/oncotarget.18114

M3 - Article

VL - 8

SP - 91703

EP - 91710

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 53

ER -